View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
August 6, 2018

Abbott’s Infinity DBS system gains MRI-labelling

The US Food and Drug Administration (FDA) has granted approval to Abbott to upgrade the software of its Infinity Deep Brain Stimulation (DBS) System designed to treat patients with Parkinson’s disease and essential tremor.

The US Food and Drug Administration (FDA) has granted approval to Abbott to upgrade the software of its Infinity Deep Brain Stimulation (DBS) System designed to treat patients with Parkinson’s disease and essential tremor.

Free Whitepaper
img

6 Keys to Simplified Labeling Changes in Life Sciences

If you are responsible for managing the change process of labels and related components, or if you’re a stakeholder in the process, you likely have a good understanding of its complexities and challenges. From automated quality checks to organisational change management, leading life sciences label management experts Esko explores here six ways you can simplify label changes and help mitigate the risk of costly – or fatal - labelling errors.
by Esko
Enter your details here to receive your free Whitepaper.

The over-the-air upgrade is set to add magnetic resonance (MR)-conditional labelling and various advanced features to the DBS device.

Before the upgrade, patients using DBS therapy could not access these features due to the potential requirement for an MRI in the future.

“The Infinity DBS system comprises directional leads that send stimulation to target areas of the brain in order to enhance patient outcomes and minimise side effects.”

The approved labelling will allow the use of the improved Infinity device, which is said to be the first FDA-cleared MR-conditional directional DBS system.

Existing implanted Infinity systems can be upgraded through secure Bluetooth wireless technology, eliminating the need for surgery.

Abbott movement disorders medical director Binith Cheeran said: “With this software upgrade, Abbott delivers on a promise to develop powerful features that strengthen the Infinity DBS system’s already patient-centric platform, which uses familiar Apple technology and frees the patient from recharging their device.

“We are committed to continued innovation in neuromodulation, developing ongoing advancements and efficiencies for physicians and, most importantly, helping thousands of people who are battling movement disorders live fuller lives.”

The Infinity DBS system comprises directional leads that send stimulation to target areas of the brain in order to enhance patient outcomes and minimise side effects.

Abbott designed the device to support any capability upgrades and the addition of new therapy features via simple, over-the-air updates.

The system also has the European CE-Mark, along with approvals in around 30 other countries such as Russia, Saudi Arabia and Taiwan.

Related Companies

Free Whitepaper
img

6 Keys to Simplified Labeling Changes in Life Sciences

If you are responsible for managing the change process of labels and related components, or if you’re a stakeholder in the process, you likely have a good understanding of its complexities and challenges. From automated quality checks to organisational change management, leading life sciences label management experts Esko explores here six ways you can simplify label changes and help mitigate the risk of costly – or fatal - labelling errors.
by Esko
Enter your details here to receive your free Whitepaper.

Topics in this article: ,
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network